Skip to content
Screener

Total Equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$22.32B+28.0%
Amgen logo
AmgenAMGN
$11.69B+57.4%
WHW
Whitehawk TherapeuticsWHWK
$116.18M-47.6%
Aura Biosciences, Inc. logo
Aura Biosciences, Inc.AURA
$107.25M-16.2%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$391.51M+135%
Eikon Therapeutics, Inc. logo
Eikon Therapeutics, Inc.EIKN
$550.67M+186%

Other financials

Income statement

See full
Revenue$6.6M
Operating income-$108.5M-28.6%
Net income-$98.5M-36.5%
EPS (diluted)-$1.11-35.4%

Balance sheet

See full
Cash & equivalents$157.5M+21.2%
Total debt$28.6M+10.1%
Total assets$1.0B-6.4%

Cash flow

See full
Operating cash flow-$75.2M-24.6%
CapEx$967.0K-27.3%
Free cash flow-$76.1M-23.5%

Valuation

See full
Market cap$3.49B+68.5%
Enterprise value$3.36B+69.4%
P/S15×+10.3×

Profitability

See full
Operating margin-4,671.1%-5,434pp
Net margin-3,921.1%-4,562pp
FCF margin-3,592%-4,290pp

Returns & leverage

See full
Return on equity-14.3%-5.0pp
Debt / equity0.0×
Current ratio10.7×-3.2×

Where this comes from

Reported directly by IDEAYA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:05 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-206357
Line itemMarch 31, 2026December 31, 2025
Stockholders’ equity
Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of March 31, 2026 and December 31, 2025; no shares issued and outstanding as of March 31, 2026 and December 31, 2025
Common stock, $0.0001 par value, 300,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 87,856,154 and 87,796,561 shares issued and outstanding as of March 31, 2026 and December 31, 202599
Additional paid-in capital1,772,8301,757,197
Accumulated other comprehensive (loss) income(494)2,267
Accumulated deficit(835,078)(736,539)
Total stockholders’ equity937,2671,022,934
Total liabilities and stockholders’ equity$1,030,348$1,109,324

Item 1. Financial Statements (UNAUDITED).

FAQ

What is IDEAYA Biosciences, Inc.'s total equity?
IDEAYA Biosciences, Inc. (IDYA) reported total equity of $937.27M in Q1 2026.
How has IDEAYA Biosciences, Inc.'s total equity changed year-over-year?
IDEAYA Biosciences, Inc.'s total equity decreased by 8.5% year-over-year, from $1.02B to $937.27M.
What is the long-term trend for IDEAYA Biosciences, Inc.'s total equity?
Over 5 years (2020 to 2025), IDEAYA Biosciences, Inc.'s total equity has grown at a 38.8% compound annual growth rate (CAGR), from $198.27M to $1.02B.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about IDEAYA Biosciences, Inc.'s total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude